Arthrosi Therapeutics

Arthrosi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for chronic inflammatory diseases, with a primary emphasis on gout treatment. The company’s lead product candidate, AR882, is a selective uric acid reabsorption inhibitor designed to address hyperuricemia and its associated complications. Arthrosi generates revenue through partnerships, licensing agreements, and potential future commercialization of its therapies. Founded in 2018, the company has made significant strides in advancing precision medicine for gout, aiming to improve patient outcomes through cutting-edge research and development.

Recent Posts by Arthrosi Therapeutics

1-1 of 1